InVitae

InVitae

Bringing comprehensive, affordable, expert genetic insights into mainstream medical care. To read our community guidelines, visit https://t.co/mWqD4UMDer.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor investor investor investor

€0.0

round
investor investor investor investor investor investor investor investor investor investor investor investor

€0.0

round
N/A

€0.0

Valuation: €0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

Valuation: €0.0

round
N/A

€0.0

round
*

$239m

Valuation: $239m

Acquisition
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2019202020212022202320242025
Revenues0000000000000000000000000000
% growth47 %29 %65 %12 %(6 %)8 %10 %
EBITDA0000000000000000000000000000
% EBITDA margin(107 %)(231 %)(146 %)(109 %)(40 %)(42 %)(32 %)
Profit0000000000000000000000000000
% profit margin(112 %)(218 %)(82 %)(602 %)(295 %)(63 %)(57 %)
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue65 %86 %90 %78 %---

Source: Company filings or news article, Equity research estimates

More about InVitae
Made with AI
Edit

Invitae (website: invitae.com) is a pioneering company in the field of genetic testing, aiming to integrate genetic information into everyday medical practice. The company's mission is to make genetic testing affordable and accessible, thereby improving healthcare for a broad range of patients. Invitae serves a diverse clientele, including individuals with a personal or family history of genetic conditions such as breast, ovarian, colorectal, or uterine cancer, as well as those seeking proactive health insights or reproductive health information.

Operating in the healthcare and biotechnology market, Invitae leverages advanced technology to provide comprehensive and reliable genetic tests. Their offerings include diagnostic tests for hereditary conditions, reproductive health screenings, and proactive health assessments. Additionally, Invitae runs sponsored testing programs, which provide no-cost testing for specific conditions, such as long chain fatty acid oxidation disorders.

The company's business model revolves around making genetic testing more accessible by reducing costs and simplifying the process for both clinicians and patients. Invitae generates revenue through several channels: direct payments from patients, insurance reimbursements, and sponsored testing programs. They offer a patient pre-pay option, which allows individuals to pay a flat fee of $250 for certain tests, making it easier for those without comprehensive insurance coverage to access their services.

Invitae's platform is designed to be user-friendly, enabling easy ordering of test kits, scheduling of sample pickups, and tracking of test results. By focusing on affordability and accessibility, Invitae aims to democratize genetic information, empowering patients and healthcare providers with actionable insights that can lead to better health outcomes.

Keywords: genetic testing, healthcare, biotechnology, diagnostics, reproductive health, proactive health, affordable, accessible, insurance, patient care.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by InVitae

Edit
One Codex
ACQUISITION by InVitae Feb 2021
Good Start Genetics
ACQUISITION by InVitae Jul 2017
AltaVoice
ACQUISITION by InVitae Jan 2017
CancerGene Connect (Ommdom)
ACQUISITION by InVitae Jun 2017
Clear Genetics
ACQUISITION by InVitae Nov 2019
CombiMatrix
ACQUISITION by InVitae Jul 2017
ArcherDX
ACQUISITION by Integrated DNA Technologies Dec 2022
Ciitizen
ACQUISITION by InVitae Sep 2021